Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Weekly News Recap #Phispers
API SUPPLIERS
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Mesochem is focused on incessant innovation along with the R&D of new APIs.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Lead Product(s) : EG-007,Pembrolizumab,Lenvatinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
Details : EG-007 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Endometrial Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : EG-007,Pembrolizumab,Lenvatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EG-007 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Endometrial Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : AMX-818,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Vir Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Vir Biotech Closes Global License Deal with Sanofi For T-Cell Engagers
Details : Through the license agreement, Vir Biotechnology will gain the rights of three clinical-stage masked TCEs, which include SAR446309 (AMX-818) for the treatment of HER2-mutated Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 09, 2024
Lead Product(s) : AMX-818,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Vir Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Vir Biotechnology Expands with Worldwide License Agreement with Sanofi for T-cell Engagers
Details : Through the license agreement, Vir Biotechnology will gain the rights of three clinical-stage masked TCEs, which include SAR446309 (AMX-818) for the treatment of HER2-mutated Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
August 01, 2024
Lead Product(s) : THOR-707,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THOR-707 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 05, 2022
Lead Product(s) : THOR-707,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THOR-707 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Esophageal Squamous Cell Carcinoma.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : Pembrolizumab,SAR444245
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pembrolizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 29, 2021
Lead Product(s) : THOR-707,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THOR-707 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mesothelioma.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 07, 2021
Lead Product(s) : Tusamitamab Ravtansine,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tusamitamab Ravtansine is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Vociprotafib,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Revolution Medicines | Mirati Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAR442720 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Solubilizers
Parenteral
Thickeners and Stabilizers
Topical
Surfactant & Foaming Agents
Emulsifying Agents
Film Formers & Plasticizers
Taste Masking
Coating Systems & Additives
Co-Processed Excipients
Direct Compression
Rheology Modifiers
API Stability Enhancers
Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
APIs
Reply
05 Aug 2022
Reply
02 Aug 2022
Reply
29 Mar 2022
Reply
14 Jan 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
Comment (4)
